RecruitingNCT07604467

The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome

Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome


Sponsor

University Medical Centre Ljubljana

Enrollment

40 participants

Start Date

Sep 6, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cd34+ stem cells, cardiac contractility recovery, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia

Ljubljana, Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07604467


Related Trials